Copy to clipboard 
NuVasive posted 1Q19 revenue of USD $274.8MM, +5.5% vs. 1Q18.
- NuVasive reiterated their previously provided 2019 guidance of $1.14 to $1.16 billion
- Growth driven by U.S. spinal hardware on the strength of new products launched in late 2018
- Advanced Material Science products like COHERE and TLIF Porous PEEK are up nearly 70% year over year
- PRECICE product line being expanded with STRYDE nail launching in May 2019 and a bone transport system later in the year
- Biologics down -6% as expected by the company, with increased volume offset by declining average selling prices due to shift away from high-end Osteocel to lower-cost products
- Experienced sales uptick in XLIF and ALIF franchises due to launch of X360 system, an integrated approach and instrument package that enables surgeons to access L5 to S1 without the need to reposition the patient
- Progress in commercializing Pulse is continuing ahead of the late 2Q19 launch, with pre-order selling under way
- Progress on robotic portion of Pulse will be shown at NASS in September 2019
- Leadership remains cautiously optimistic that the global spine market will not change much from 2018
- Price pressure for spinal hardware products was 2.4% for the quarter
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).
| 1Q19 | 1Q18 | $ Chg | % Chg | |
| Spine | $241.3 | $225.8 | $15.4 | 6.8% |
| Trauma | $9.1 | $8.7 | $0.4 | 4.6% |
| Orthobiologics | $24.4 | $26.0 | -$1.6 | -6.0% |
| Total | $274.8 | $260.5 | $14.3 | 5.5% |
ORTHOWORLD estimates NuVasive’s orthopaedic revenue by geographic region as follows ($MM).
| Geographic Region | 1Q19 | 1Q18 | $ Chg | % Chg |
| US | $222.8 | $213.3 | $9.5 | 4.5% |
| Ex-US | $52.0 | $47.2 | $4.7 | 10.0% |
| EMEA | $42.35 | $37.78 | $4.6 | 12.1% |
| Asia Pacific | $5.33 | $4.72 | $0.6 | 12.8% |
| Rest of World | $4.29 | $4.72 | -$0.4 | -9.2% |
| Total | $274.8 | $260.5 | $14.3 | 5.5% |
Net earnings are as follows.
| 1Q19 | Amount ($MM) | % of Sales |
| Sales | $274.8 | |
| Cost of Sales | -$74.5 | 27.1% |
| R & D | -$17.6 | 6.4% |
| Selling and Admin | -$145.1 | 52.8% |
| Other | -$28.2 | 10.3% |
| Net Earnings | $9.4 | 3.4% |
Sources: NuVasive; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
NuVasive posted 1Q19 revenue of USD $274.8MM, +5.5% vs. 1Q18.
NuVasive reiterated their previously provided 2019 guidance of $1.14 to $1.16 billion
Growth driven by U.S. spinal hardware on the strength of new products launched in late 2018
Advanced Material Science products like COHERE and TLIF Porous PEEK are up nearly 70% year...
NuVasive posted 1Q19 revenue of USD $274.8MM, +5.5% vs. 1Q18.
- NuVasive reiterated their previously provided 2019 guidance of $1.14 to $1.16 billion
- Growth driven by U.S. spinal hardware on the strength of new products launched in late 2018
- Advanced Material Science products like COHERE and TLIF Porous PEEK are up nearly 70% year over year
- PRECICE product line being expanded with STRYDE nail launching in May 2019 and a bone transport system later in the year
- Biologics down -6% as expected by the company, with increased volume offset by declining average selling prices due to shift away from high-end Osteocel to lower-cost products
- Experienced sales uptick in XLIF and ALIF franchises due to launch of X360 system, an integrated approach and instrument package that enables surgeons to access L5 to S1 without the need to reposition the patient
- Progress in commercializing Pulse is continuing ahead of the late 2Q19 launch, with pre-order selling under way
- Progress on robotic portion of Pulse will be shown at NASS in September 2019
- Leadership remains cautiously optimistic that the global spine market will not change much from 2018
- Price pressure for spinal hardware products was 2.4% for the quarter
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).
| 1Q19 | 1Q18 | $ Chg | % Chg | |
| Spine | $241.3 | $225.8 | $15.4 | 6.8% |
| Trauma | $9.1 | $8.7 | $0.4 | 4.6% |
| Orthobiologics | $24.4 | $26.0 | -$1.6 | -6.0% |
| Total | $274.8 | $260.5 | $14.3 | 5.5% |
ORTHOWORLD estimates NuVasive’s orthopaedic revenue by geographic region as follows ($MM).
| Geographic Region | 1Q19 | 1Q18 | $ Chg | % Chg |
| US | $222.8 | $213.3 | $9.5 | 4.5% |
| Ex-US | $52.0 | $47.2 | $4.7 | 10.0% |
| EMEA | $42.35 | $37.78 | $4.6 | 12.1% |
| Asia Pacific | $5.33 | $4.72 | $0.6 | 12.8% |
| Rest of World | $4.29 | $4.72 | -$0.4 | -9.2% |
| Total | $274.8 | $260.5 | $14.3 | 5.5% |
Net earnings are as follows.
| 1Q19 | Amount ($MM) | % of Sales |
| Sales | $274.8 | |
| Cost of Sales | -$74.5 | 27.1% |
| R & D | -$17.6 | 6.4% |
| Selling and Admin | -$145.1 | 52.8% |
| Other | -$28.2 | 10.3% |
| Net Earnings | $9.4 | 3.4% |
Sources: NuVasive; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
